De-escalated Dual Antiplatelet Therapy
2022-ZX100
Approved small_molecule completed
Quick answer
De-escalated Dual Antiplatelet Therapy for Coronary Artery Disease is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Coronary Artery Disease
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed